Compare RGCO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | ACIU |
|---|---|---|
| Founded | 1912 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.0M | 247.6M |
| IPO Year | 2005 | 2015 |
| Metric | RGCO | ACIU |
|---|---|---|
| Price | $21.64 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.54 |
| AVG Volume (30 Days) | 9.6K | ★ 164.1K |
| Earning Date | 11-18-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 11.21 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $95,334,212.00 | N/A |
| Revenue This Year | $15.70 | $422.39 |
| Revenue Next Year | $4.44 | $377.85 |
| P/E Ratio | $15.76 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $20.55 | $2.10 |
| 52 Week High | $27.17 | $4.00 |
| Indicator | RGCO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 54.02 |
| Support Level | $20.86 | $2.58 |
| Resistance Level | $22.21 | $2.97 |
| Average True Range (ATR) | 0.50 | 0.16 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 91.78 | 66.75 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.